Deep vein thrombosis and pulmonary embolism

Nisio, Marcello Di; Es, Nick van; Büller, Harry R.

doi:10.1016/s0140-6736(16)30514-1

Cited by 715 publications

(577 citation statements)

References 155 publications

Supporting

Mentioning

540

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, all currently available anticoagulant therapies carry the burden of increased bleeding risk. After initial treatment of an episode of venous thromboembolism (typically 3‐6 months), the decision to prolong anticoagulant treatment must be weighed against the bleeding risk 1. Ideally, persons with a high recurrence risk are identified and anticoagulant treatment prolonged, whereas in patients with a low recurrence risk, treatment can be stopped safely.…”

Section: Introductionmentioning

confidence: 99%

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Scheres

Lijfering

Cheung

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

BackgroundPrediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain.ObjectiveTo assess the influence of rivaroxaban and apixaban on several coagulation factor levels.MethodsIn two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individuals immediately before intake of rivaroxaban 15 mg twice daily (n = 6) or apixaban 10 mg twice daily (n = 6) and three hours after the last intake.ResultsOverall, measured levels were lower after rivaroxaban/apixaban intake. The paired mean difference after rivaroxaban intake was −38 IU/dL (95% CI −43; −33) for FVIII:C, −29 U/dL (95% CI −45; −12) for FXI:C, −22 IU/dL (95% CI −43; −1) for FXII:C, −0.11 g/L (95% CI −0.25; 0.03) for fibrinogen, −7 IU/dL (95% CI −18; 3) for VWF:Ag, −27 ng/mL (95% CI −50; −4) for d‐dimer and −0.36 (95% CI −0.57; −0.15) for Ln d‐dimer. After apixaban intake this was −29 IU/dL (95% CI −38; −21) for FVIII:C, −29 IU/dL (95% CI −36; −22) for FXI:C, −19 IU/dL (95% CI −24; −15) for FXII:C, −0.18 g/L (95% CI −0.33; 0.03) for fibrinogen, −52 ng/mL (95% CI −100; −4) for d‐dimer, 0.25 (−0.60; 0.09) for Ln d‐dimer and 1 IU/dL (95% CI −7; 9) for VWF:Ag.Conclusion FVIII:C, FXI:C, FXII:C, and d‐dimer measurements were influenced by rivaroxaban/apixaban intake, while fibrinogen and VWF:Ag were not.

show abstract

Section: Introductionmentioning

confidence: 99%

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Scheres

Lijfering

Cheung

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…However, a timely and accurate diagnosis of PE remains challenging in our clinical practice (5). Although the diagnosis of PE was improved with the advent of D-dimer test and CT scan, there is still need for simple, reliable and non-invasive biomarker for accurate and rapid diagnosis of PE (17).…”

Section: Discussionmentioning

confidence: 99%

“…Recent diagnostic methods for PE mainly consist of biomarkers (such as D-dimer) and radiologic image examinations such as computed tomography angiography and ventilationperfusion scintigraphy (3,4). However, as a widely applied biomarker for the diagnosis of PE, the D-dimer test exhibits high sensitivity, but low specificity for the diagnosis of PE (5). Therefore, a negative result of D-dimer test was commonly used for exclusion of PE (3,6).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs are novel non-invasive diagnostic biomarkers for pulmonary embolism: a meta-analysis

Deng¹,

Li²,

Luo³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Backgrounds: The diagnosis of pulmonary embolism (PE) still remains difficult in clinical practice.MicroRNAs (miRNAs) have been widely investigated as biomarkers for various diseases. However, the diagnostic biomarker value of miRNAs in the diagnosis of PE is unclear. Therefore, we conducted this metaanalysis to establish the diagnostic power of miRNAs for PE diagnosis. Methods: A systematic literature search in PubMed and Embase was conducted to identify relevant studies dated up to July 22, 2016. Data on sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were pooled from those included studies. Summary receiver operating characteristic (SROC) curves were used to summarize overall diagnostic power of miRNAs for PE diagnosis. Results: A total of three studies with five types of miRNAs covering 254 participants were included in our meta-analysis. The overall pooled results for sensitivity, specificity, PLR, NLR, and DOR of miRNAs for PE

show abstract

“…Clinical symptoms and signs of DVT include edema, reddening, limb pain, dilation of superficial veins, calf pain during foot dorsiflexion, tenderness along the course of the vein, and increased warmth of the affected limb [21]. However, the specificity of these symptoms and signs is inadequate and thus the diagnosis cannot be made based on clinical symptoms and signs only.…”

Section: Diagnosis Of Deep Venous Thrombosis and Pulmonary Embolism Dmentioning

confidence: 99%

Venous thromboembolism — recommendations on the prevention, diagnostic approach and management. The 2017 Polish Consensus Statement

Tomkowski¹,

Kuca²,

Urbanek³

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

Deep vein thrombosis and pulmonary embolism

Cited by 715 publications

References 155 publications

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

MicroRNAs are novel non-invasive diagnostic biomarkers for pulmonary embolism: a meta-analysis

Venous thromboembolism — recommendations on the prevention, diagnostic approach and management. The 2017 Polish Consensus Statement

Contact Info

Product

Resources

About